For the purpose of informing interested University of Tennessee-Knoxville faculty, please be aware of the following opportunity. Please note that the other recipients of this announcement could be potential collaborators on this opportunity.

**RFA-HL-11-018: Clinical Centers for the Severe Asthma Research Program (SARP) (U10)**

<table>
<thead>
<tr>
<th>Letter of Intent to Agency</th>
<th>09/15/2010 -Optional</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proposal to Sponsored Programs</td>
<td>10/08/2010</td>
</tr>
<tr>
<td>Submission to Agency</td>
<td>10/15/2010</td>
</tr>
</tbody>
</table>

- **Estimated Total Funding**: $31.5M
- **Anticipated No. of Awards**: See solicitation
- **Cost Share**: No

The National Institutes of Health is **soliciting applications to participate as a Clinical Center in the NHLBI Severe Asthma Research Program (SARP)**. The purpose of this new phase of SARP is to promote collaborative, multidisciplinary research using a mechanistic-based temporal approach to achieve the following objectives:

- Integrate genetic, epigenetic, genomic and other complementary -omic approaches to identify pathobiologic processes to permit redefinition of clinical sub-phenotypes such that mechanism-based treatments can be developed and applied to precisely defined populations.

- Identify and validate biomarkers that reflect or anticipate fundamental biological processes that correlate over time with sub-phenotype progression / stability and response to treatment (with view toward developing practical biomarker-based tools to predict loss of symptom control and risk of exacerbation).

- Utilize bioinformatics approaches to facilitate integration of diverse data from various sources (e.g., GWAS, gene microarrays, clinical and molecular phenotypes, empirical data) into coherent models to enhance identification of novel molecular therapeutic targets and enable utilization and sharing of data among studies of severe asthma.
Establish a well-annotated biospecimens bank to enable studies that correlate molecular phenotyping and clinical status and to develop genomics- and proteomics-based therapies (eventually will transition to the NHLBI Biologic Specimens Repository and BioLINCC -- https://biolincc.nhlbi.nih.gov/home/).

This opportunity runs parallel with a separate FOA that solicits applications for the Clinical Coordinating Center (see RFA-HL-11-030).

To find more opportunities from this agency, please see here.

For detailed information about this opportunity please see the full solicitation. Please contact Sponsored Programs (4-5066) with questions regarding proposal submission requirements.

If you have any questions regarding this announcement, please contact:

Dr. James Lloyd
Professor and Coordinator of Electronic Research Administration
UT Knoxville Office of Research
Phone: (865) 974-0390
E-mail: jlloyd@utk.edu